Yes, it really is that simple. The cutoff time for the trial is not LPLD but LPLD plus the survival period stated in the protocol which, as exwannabe noted, is three years. You may collect more data beyond that period, you may add more data elements, or do whatever else you like, but then the analysis is not per protocol and need not be blinded. Similarly, you cannot be amending the protocol at this late date and claim that you need additional data points to perform a post hoc analysis that supports the facts; that is a thinly disguising fishing expedition that will not support a regulatory filing.
Quit making excuses for sloppy execution on a trial that began during the Bush administration. Once FDA put the trial on clinical hold and no more patients could be enrolled, the countdown began. COVID is a handy excuse for why the data is not scrubbed and in the database, but it is no more real than the proverbial dog that ate the homework. All of this should have been done a few years ago. You might ask what the company has been doing with shareholder money all that time; it sure wasn't managing the trial.